PURPOSE: There are many phase I trials of oncology drug combinations, very few of which report clinically significant pharmacokinetic interactions. We hypothesized that the utility of such pharmacokinetic drug-drug interaction (DDI) studies is low in the absence of a mechanistic hypothesis. EXPERIMENTAL DESIGN: We retrospectively reviewed 152 phase I (two drug) combination studies published between 2007 and 2011. RESULTS: Only 28 (18%) studies had an implicit or explicit rationale, either inhibition/induction of a drug-metabolizing enzyme or transporter, cosubstrates for the same enzyme or transporter, potential for end-organ toxicity, or protein binding. Only 12 (8%) studies demonstrated a statistically significant DDI, on the basis of change in clearance (or area under the curve) of parent drug and/or active metabolite. There was a strong association between a rationale and a demonstrable drug interaction, as only 2% of studies without a rationale demonstrated a DDI, compared with 32% of studies with a rationale (Fisher exact test; P < 10(-6)). CONCLUSION: DDI studies should not be routinely performed as part of phase I trials of oncology combinations.
PURPOSE: There are many phase I trials of oncology drug combinations, very few of which report clinically significant pharmacokinetic interactions. We hypothesized that the utility of such pharmacokinetic drug-drug interaction (DDI) studies is low in the absence of a mechanistic hypothesis. EXPERIMENTAL DESIGN: We retrospectively reviewed 152 phase I (two drug) combination studies published between 2007 and 2011. RESULTS: Only 28 (18%) studies had an implicit or explicit rationale, either inhibition/induction of a drug-metabolizing enzyme or transporter, cosubstrates for the same enzyme or transporter, potential for end-organ toxicity, or protein binding. Only 12 (8%) studies demonstrated a statistically significant DDI, on the basis of change in clearance (or area under the curve) of parent drug and/or active metabolite. There was a strong association between a rationale and a demonstrable drug interaction, as only 2% of studies without a rationale demonstrated a DDI, compared with 32% of studies with a rationale (Fisher exact test; P < 10(-6)). CONCLUSION: DDI studies should not be routinely performed as part of phase I trials of oncology combinations.
Authors: Jane R Kenny; Sophie Mukadam; Chenghong Zhang; Suzanne Tay; Carol Collins; Aleksandra Galetin; S Cyrus Khojasteh Journal: Pharm Res Date: 2012-03-14 Impact factor: 4.200
Authors: Lang Li; Menggang Yu; Raymond Chin; Aroonrut Lucksiri; David A Flockhart; Stephen D Hall Journal: Stat Med Date: 2007-09-10 Impact factor: 2.373
Authors: Jihao Zhou; Zhaohui Qin; Sara K Quinney; Seongho Kim; Zhiping Wang; Menggang Yu; Jenny Y Chien; Aroonrut Lucksiri; Stephen D Hall; Lang Li Journal: J Pharmacokinet Pharmacodyn Date: 2009-01-21 Impact factor: 2.745
Authors: Amina Haouala; Nicolas Widmer; Michel A Duchosal; Michael Montemurro; Thierry Buclin; Laurent A Decosterd Journal: Blood Date: 2010-09-01 Impact factor: 22.113
Authors: George D Demetri; Paolo G Casali; Jean-Yves Blay; Margaret von Mehren; Jeffrey A Morgan; Rossella Bertulli; Isabelle Ray-Coquard; Philippe Cassier; Monica Davey; Hossein Borghaei; Daniel Pink; Maria Debiec-Rychter; Wing Cheung; Stuart M Bailey; Maria Luisa Veronese; Annette Reichardt; Elena Fumagalli; Peter Reichardt Journal: Clin Cancer Res Date: 2009-09-01 Impact factor: 12.531
Authors: Channing J Paller; Penelope A Bradbury; S Percy Ivy; Lesley Seymour; Patricia M LoRusso; Laurence Baker; Larry Rubinstein; Erich Huang; Deborah Collyar; Susan Groshen; Steven Reeves; Lee M Ellis; Daniel J Sargent; Gary L Rosner; Michael L LeBlanc; Mark J Ratain Journal: Clin Cancer Res Date: 2014-08-15 Impact factor: 12.531
Authors: Salvador Fudio; Alvaro Sellers; Laura Pérez Ramos; Beatriz Gil-Alberdi; Ali Zeaiter; Mikel Urroz; Antonio Carcas; Rubin Lubomirov Journal: Cancer Chemother Pharmacol Date: 2022-08-27 Impact factor: 3.288